新京报讯3月9日，和黄医药（中国）有限公司（简称“和黄医药”）发布公告宣布，公司附属公司和记黄埔医药（上海）有限公司（简称“和记黄埔”）已启动在中国内地、中国香港和中国澳门撤市并召回达唯珂（他泽司他），并停止所有正在进行的他泽司他的临床试验。 达唯珂是和黄医药由益普生（Ipsen）旗下公司Epizyme,Inc.（简称“Epizyme”）授权引进的肿瘤治疗药物，Epizyme为达唯珂在中国内地的...
Source Link新京报讯3月9日，和黄医药（中国）有限公司（简称“和黄医药”）发布公告宣布，公司附属公司和记黄埔医药（上海）有限公司（简称“和记黄埔”）已启动在中国内地、中国香港和中国澳门撤市并召回达唯珂（他泽司他），并停止所有正在进行的他泽司他的临床试验。 达唯珂是和黄医药由益普生（Ipsen）旗下公司Epizyme,Inc.（简称“Epizyme”）授权引进的肿瘤治疗药物，Epizyme为达唯珂在中国内地的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.